|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
The REXO1L1 gene product is a marker of hepatitis C virus (HCV) infection and a possible association between REXO1L1 copy number and susceptibility to HCV infection, progression or response to treatment has not yet been excluded.
|
24045839 |
2014 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Testing for anti-GOR IgG in patients in whom HCV RNA is not detected in their sera may help with the identification of a subset of patients with occult HCV infection without the need to perform a liver biopsy.
|
17699833 |
2007 |
|
REXO1L1P
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Testing for anti-GOR IgG in patients in whom HCV RNA is not detected in their sera may help with the identification of a subset of patients with occult HCV infection without the need to perform a liver biopsy.
|
17699833 |
2007 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, many patients with chronic hepatitis C virus infection have reactivity to an autoantigen of unknown significance known as GOR that has protein sequence homology with both hepatitis C virus nucleocapsid protein as well as HTLV-1 gag.
|
10604234 |
1999 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positivity for anti-GOR among the group with GBV-C/HGV RNA alone was significantly lower than that among the groups with HCV RNA (P < 0.01 and P < 0.05, respectively).
|
9598933 |
1998 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed cryoglobulinemia, purpura, arthritis, proteinuria, decreased complement levels, rheumatoid factor and anti-GOR, smooth muscle antibody (SMA), anti-nuclear antibody (ANA), and liver, kidney microsome (LKM) autoantibodies were significantly more represented in HCV positive patients than in negative ones (P < .05).
|
8938157 |
1996 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reactivity to the GOR autoepitope correlates with HCV core response and liver necroinflammatory activity, thus suggesting an immunopathogenic role in chronic hepatitis C.
|
8568289 |
1996 |
|
REXO1L1P
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Autoimmune reactivity associated with HCV infection was evaluated by using a synthetic peptide derived from the GOR peptide; 8/11 HCV-positive sera were found reactive against this peptide.
|
8822625 |
1996 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients infected with hepatitis C virus (HCV) were examined with four commercial HCV immunoblotting assays and for anti-GOR antibody to ascertain whether serological findings varied with the genotype of the infecting virus.
|
7535312 |
1995 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, reactivity to GOR was not related to any certain serotype of antibodies to HCV.
|
7516270 |
1994 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patient did not produce anti-HCV and anti-GOR antibodies throughout the study and had no histological evidence of hepatitis.
|
8194716 |
1994 |
|
REXO1L1P
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating HCV-RNA levels but not anti-HCV or anti-GOR antibodies correlated with hepatocellular damage.
|
7682256 |
1993 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, anti-HCV II was more sensitive in detecting HCV infection than either anti-c100 or anti-GOR (P < 0.001).
|
7685043 |
1993 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data indicate that antibodies to GOR is a marker associated with NANBH.
|
1383257 |
1992 |
|
REXO1L1P
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of anti-GOR would therefore help in the diagnosis of NANBH and in reducing the occurrence of post-transfusion hepatitis.
|
1701012 |
1990 |